

AMICUS THERAPEUTICS INC
Form 8-K
April 29, 2014

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **April 29, 2014**

AMICUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other Jurisdiction of Incorporation)

001-33497
(Commission File Number)

71-0869350
(IRS Employer Identification No.)

1 Cedar Brook Drive, Cranbury, NJ
(Address of Principal Executive Offices)

08512
(Zip Code)

Registrant's telephone number, including area code: **(609) 662-2000**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Edgar Filing: AMICUS THERAPEUTICS INC - Form 8-K

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure.

On April 29, 2014, Amicus Therapeutics, Inc. (the Company) hosted a conference call and webcast to discuss the positive 12 and 24 month data results from its Phase 3 Fabry Monotherapy Study 011. A copy of conference call presentation materials is attached hereto as Exhibit 99.1.

Item 8.01. Other Events.

On April 29, 2014, the Company issued a press release announcing the positive 12 and 24 month data results from its Phase 3 Fabry Monotherapy Study 011. A copy of this press release is attached hereto as Exhibit 99.2.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits: The Exhibit Index annexed hereto is incorporated herein by reference.

Exhibit No.	Description
99.1	April 29, 2014 Conference Call Presentation Materials
99.2	Press Release dated April 29, 2014 titled Amicus Therapeutics Announces Positive 12- and 24-Month Data from Phase 3 Fabry Monotherapy Study 011.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMICUS THERAPEUTICS, INC.

Date: April 29, 2014

By: /s/ WILLIAM D. BAIRD III
Name: William D. Baird III
Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	April 29, 2014 Conference Call Presentation Materials
99.2	Press Release dated April 29, 2014 titled Amicus Therapeutics Announces Positive 12- and 24-Month Data from Phase 3 Fabry Monotherapy Study 011.